Substance Use in Youth





James McKowen, PhD Clinical Director Addiction Recovery Management Service (ARMS) Massachusetts General Hospital Assistant Professor, Harvard Medical School

DISCLOSURES

Neither I nor my spouse/partner has a relevant financial relationship with a commercial interest to disclose.


10/2/2023

10/2/2023


OVERVIEW OF TALK:

• Trends in use


- Review Alcohol, Nicotine, Opioids, & Cannabis
- Neurobiological impacts of Cannabis
- Health Effects of Cannabis
- Impact of Legalization of Cannabis
- Challenges with youth substance use
- $\ensuremath{^\bullet}$ Assessment and continuum of substance use
- Evidence-based Treatments
- Parental Role in Treatment


































- Puffing activates the battery-powered heating device, which vaporizes the liquid in the cartridge. The person then inhales the resulting aerosal or vapor (called vaping). It does not contain water – myth.
- Nicotine stimulates adrenal gland to release adrenaline and dopamine (effect lasts 10-30mins).

E-CIG/VAP AND TEENS



- Most commonly used form of Nicotine
- $\bullet\,$ E-Cig use by 9th grade predicts later Cigarette use
- E-Cig users 6-7 x more likely to use regular cigarettes, but cig users no more likely to use e-cig.
- Tobacco rates down, vaping rates up

• Nicotine and mental health:

- S.
- Early onset psychopathology → increased risk
 Nicotine use → more mood lability, worse depression
- Higher medication dosage, more hospitalizations, greater symptoms compared mental illness + non-smoking.

10/2/2023

Morris et al, 2011; Fishcer et al, 2012; NIDA, 2016

DO THEY HELP YOU QUIT?

• Lab based studies suggest:


- Harm reduction fewer chemicals
- Can reduce cravings/urges
- May be equivalent to NRT
- Limited real-world examination


• Cochrane Review:

• May help quit in long-term but strength of evidence is low, esp in youth

10/2/2023

Brown et al, 2016; Kalkhoran et al, 2016; Hartman-Boyce et al, 2016, Erku et al, 2020







CANNABIS DOSES

Toward standard cannabis doses

- 1 serving or dose of THC = $10mg \frac{1}{2}$ of the dosage that can get naïve user high
- Average joint is 0.3 grams (300mg); a blunt (wrapped in tobacco paper) may be much larger
- 0.3 g joint containing 20% THC gives 60mg of THC (6 doses)
- Inhalation yields about 1/3 1/2 the amount of the THC \rightarrow 2-3 doses per joint
- Yield varies by type of inhalation (vaping more effective, with 50% yield)



Inhaled versus oral ingestion of THC

- Smoking or Vaping:
 - Onset seconds minutes
 - Peak 30 minutes
 - Duration 1-3.5 hours

Oral ingestion:

- Onset 30 minutes 2 hours
- Peak 2-3 hours
- Duration 5-8 hours (or longer)

• Edible serving size in commercial products varies and is confusing



Joint (or spliff) versus blunt

10/2/2023

Serving Size 1/2 duater (10.5 g) 10mg THC per serving, servings per container 8 Anose per serving, Caloria 4, Caloria Hom Fil 223, Hall Fil 23g (HKV), Sanzerd E 0.5 g/(HKV), Hom Fil (B/KV), Calorizend Mg (HKV), Sanzer Fil (B/KV), Sanz Calorizend Mg (HKV), Sanzer File 0.5 g/(HKV), Sanzer F

10/2/2023

CBD PRODUCTS


- Increasing number of products available in stores or online that purport to contain CBD
- One study of "CBD" vaping products sold online found CBD + THC, synthetic cannabinoids (such as K2), and dextromethorphan.
- Only 30% of advertised vaping products had labeling that accurately reported their ingredients, and 21% contained unreported THC.
- Some products are Federally illegal and separate from state medical / recreational cannabis systems, so no oversight.







Compound	Administration	FDA Status	Approved Locations	Purposes
Dronabinol (Marinol) THC analog	Oral capsule 2.5-5 mg QD	FDA-approved (1985)	USA, Germany	 Nausea & vomiting relate to cancer chemotherapy Wasting associated with AIDS
Nabilone (Cesamet) THC analog	Oral capsule 1-2 mg BID	FDA-approved (1985) *Marketed in the US in 2006	USA, Canada, UK, Mexico	 Nausea & vomiting relate to cancer chemotherapy
Nabiximols (Sativex) Extract (THC + CBD)	Oromucosal spray 1-6 sprays BID	Almost FDA- approved; late- stage clinical trials	Canada, UK, other European countries	Multiple sclerosis spasticit; cancer pain neuropathic pain
Cannabidiol (Epidiolex) Extract	Oral solution 2.5-5 mg/kg BID	FDA-approved (2018)	USA	Seizures (Lennox-Gastaut and Dravet Syndromes)





















































THERAPEUTIC FINDINGS		
CONCLUSIVE OR SUBSTANTIAL • Chronic pain • Antiemetics for chemo-induced nausea/vo	 MS spasticity symptoms omiting 	
MODERATE • ↑ short-term sleep in obstructive sleep apr MS	nea syndrome, fibromyalgia, chronic pain,	
LIMITED • † appetite and ↓ weight loss associated w/ HIV/AIDS • ↓ symptoms of Tourette syndrome	 J anxiety in social anxiety disorders J PTSD symptoms Improve outcomes (i.e. disability) after traumatic brain injury 	
NO OR INSUFFICIENT • Canceras, including glioma • Canceraseociated ancrexia cachexia syndrome and anorxía nervosa • Symptoms of intlable bowel syndrome • Epilepsy • ALS symptoms • Drotonia	Chorea and certain symptoms associated w/ Huntington's Motor system symptoms associated w/ Parkinson's disease (5 passibit) in patients w/ paralysis due to spins cord injury Abstinence in the use of addictive substances Outcomes in individuals w schizophrenia	

I

MEDICAL RISKS		
CONCLUSIVE OR SUBSTANTIAL • ↑ respiratory symptoms and chronic bronchitis episodes	 ↑ motor vehicle crashes ↑ lower birth weight of offspring 	
MODERATE •	CESSATION of cannabis use associated w/ improvements in respiratory symptoms <u>NO</u> association w/ lung, head and neck cancers	
LIMITED ↑ prediabetes ↑ COPD ↑ acute MI or stroke ↑ pregnancy complications	† non-seminoma-type testicular tumors J production of several inflammatory cytokines † admission of infant to neonatal ICU ↓ metabolic syndrome and diabetes	
NO OR INSUFFICIENT • Esophageal, bladder, prostate, cervical, penile, and anal cancer, malignant gliomas, non- Hodgkin lymphoma, Kaposi's sarcoma, leukemia, rhabdomyosarcoma, astrocytoma, or neuroblastoma in offspring • Asthma development or asthma exacerbation	Hospital admissions for COPD All-cause mortality Occupational accidents or injuries Death due to cannabis overdose Later outcomes in offspring (e.g., sudden infant death syndrome, cognition/academic achievement, and later substance use	



MENTAL HEAL	TH RISKS	
CONCLUSIVE OR SUBSTANTIAL • † schizophrenia or other psychoses, w/ hig	hest risk among most frequent users	
MODERATE	↑ social anxiety disorder	
 ↑ Impairment in learning, memory, and attention 	 	
	 Better cognitive performance among individuals w/ psychotic disorders and a bit tags of connability 	
 ↑ suicidal ideation/attempts/completion w/ higher incidence among heavier users 	disorders and a history of cannabi use vs. those w/out history of cannabis use	
LIMITED	↑ positive symptoms of	
 ↑ unemployment/low income rates 	schizophrenia (e.g., hallucinations	
 ⊥ social functioning and developmentally 	 ↑ anxiety symptoms ↑ PTSD severity ↑ development of bipolar or any anxiety disorder, except social anxiety disorder 	
appropriate social roles		
 Sustained abstinence continues to be associated ↓ cognitive domains of learning, memory, and attention 		
NO OR INSUFFICIENT • Development of PTSD	Changes in course of depressive disorders 10/2/2023	




<u>† Risk to develop problem cannabis use</u> Initiating cannabis use at earlier age Increases in cannabis use frequency Being male and smoking cigarettes	Stimulant treatment of ADHD during adolescence is NOT a risk factor for the development of problem cannabis use	
MODERATE	↑ PTSD severity	
	NOT Associated w/ Developing Problem Cannabis Use	
 Major depressive disorder In Adolescents: cannabis use frequency, 	 Neither alcohol nor nicotine dependence alone 	
oppositional behaviors, younger age of first alcohol use, nicotine use, parental substance use, poor	 Anxiety, personality disorders, or bipolar disorders 	
school performance, antisocial behaviors, and sexual abuse		
LIMITED • The initiation of tobacco use • Changes in use patterns of other substances	 Childhood anxiety / depression are risk factors for development of problem cannabis use 	

Marijuana and Youth Aggression




- Anecdotal in clinic & schools Yes
- Data is mixed
 - White, 1998: 4 waves of data assessed 12 y/o \rightarrow 28 years
 - Adolescent MJ predicted later aggression
 - Early aggression didn't predict later MJ use
 - Lui, 2013: Early aggression, in boys, predicts MJ use only
 - Ansell, 2015: Smarphone readings: MJ and Aggression not related McKowen et al 2022: higher self-report anger →THC concentration, usage, CUD dx
- During withdrawal phase: more supportive data:
 Budney, 2003: During withdrawal peak 2-6 days up to 20 days - Millin 2008: 13-19 y/o, anger increased in 1st two weeks, up to $3^{\rm rd}$ week.














Executive Function Measured	Acute Effects (0-6 hrs)	Residual Effects (7hrs-20 days)	Long-Term Effects (21 days +)
Attention/Concentration	Impaired (light users) Normal (heavy users)	Mixed findings	Largely normal
Decision Making & Risk Taking	Mixed findings	Impaired	Impaired
Inhibition/Impulsivity	Impaired	Mixed findings	Mixed findings
Working Memory	Impaired	Normal	Normal
Verbal Fluency	Normal	Mixed findings	Mixed findings
			10/2/2023





































































EFFECTIVENESS OF LOC:



• Inpatient / Section 35 (Involuntary 3-90 days)

- Lower incidence of suicide attempts & absconding
- Section 35: 7 studies showed negative outcomes & 2 positive
- Involuntary admission 1.4 x more likely to die of OD (issue of treatment initiation pre-d/c)
- No systematic evidence in youth not yet sufficient evidencebased treatment
- Residential (Voluntary 24 hrs 30 days+)
 - Effective in reducing severity, craving, & improving MH
 - Limited data on length of sustained effect

Gray & Argez, 2019 CADTH, SAMHSA, 202,0; Uliaszek et al 2019, Section 35 Commission, 2019; Vuong et al., 2019

CONT'D • Outpatient: • Partial Hospital Program (Daily, 9-2pm ish) • Intensive Outpatient Program (9 Hrs p/w) • Outpatient (< 9 hrs p/w) Systemic review of 12 studies:



10/2/2023

- Strong evidence all outpatient LOC are effective, some review suggest PHP and IOP equivalent to residential LOC

- Caveats:

- EBT and pharm intervention key
- Limited data on racial/ethnicity differences

10/2/2023

McCarty et al, 2014 Psychatric Serv.


EVIDENCE BASED THERAPY INTERVENTIONS


Strong Empirical Evidence:

- Motivational Enhancement Therapy (MET)
- Contingency Management (CM)
- CBT Individual and Group therapy (CBT-I/G)
- Brief Strategic Family Therapy (BSFT)
- Behavioral Couples Therapy (BCT)
- Twelve Step Facilitation (TSF) Emerging evidence
- Integrated Dual Disorders Treatment (IDDT) in CJS





10/2/2023











OTHER PHARM TREATMENTS:

• Cannabis

- No FDA approved medications
- NAC, Naltrexone, gabapentin, SSRI (weak evidence)
- Dronabinol (maybe for w/d) (limited data)
- $^{\bullet}\,$ Nabilone (some help w/ anxiety) (limited data)

• Cocaine

- No FDA approved medications
- Modafinil and Topamax (limited evidence)

Benzodiazepines

- Management of w/drawal and taper schedule $$_{10/2/2023}$$


Brett et al, 2015 Aust Presc; Kampman et al 2019 Sci Adv


PHARMACOLOGICAL CANNABIS INTERACTIONS

• THC can impact effectiveness of medications by reducing or potentiating their effects:

- Sedatives: Ambien, Lunesta, Benadryl
- Anti-anxiety: Xanax, Valium, Librium, clobazam
- Anti-depressant: Zoloft Prozac, Lexapro
- Anti-psychotic: Halopreidol, Olanzapine, Clozapine
- Pain medication: Codeine, Percocet, Vicodine
- Anti-convulsant: Tegretol, Topamax, Depakene
- Anti-coagulants coumadin, Herpainr, Plavix








STRAIN ON FAMILIES:

- Ordinary people faced with coping with an enormous stressor – typical coping is compromised
- Lee, 2011 compared to controls: greater levels of depression, stress, & isolation
- Oreo, 2007 Parents have "grief reaction" avoidance, distress, all leading to worse parentchild interaction
- Handley, 2008 youth addiction worsens parent substance use in those with low parent social support



10/2/2023



COMMUNITY REINFORCEMENT AND FAMILY TRAINING (CRAFT)



• Targeted to caregivers to help motivate youth with SUD to engage in treatment

• Goals:

- Empower with knowledge and a plan
 Improve communication, problem-solving, understanding
- Teach principals of contingency management to reinforce behavioral change
- Enhance parental self-care

10/2/2023


Meyers 1996

MGH: ARMS PROGRAM


- Recovery Management Philosophy
- Treats teens 26 year olds and their parents
- Patient centered care: motivational model & harm reduction
- Evidence-based psychosocial treatments
- Medication Treatment
- Recovery Coach



• Parent Program







THANK YOU!